Stockscreener 앱 받기
3.09
0.98%
0.03
Xenetic Biosciences Inc 주식(XBIO)의 최신 뉴스
Xenetic Biosciences (XBIO) Gains 6.7% – Bullish Breakout Within Tight RangeBreakout Stock Alerts - newsline.com
XBIO Q2 2025 Earnings: Narrower Loss Beats Estimates, Yet Stock Slips on No Revenue ProgressDividend Cut Risk - newsline.com
Xenetic Biosciences (XBIO) Secures Approval for Clinical Study i - GuruFocus
Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell Lymphoma - ACCESS Newswire
Israeli study to combine DNase I with CAR-T in large B-cell lymphoma - Stock Titan
Xenetic Biosciences (XBIO) Reports Q2 Loss, Misses Revenue Estimates - MSN
Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and Survival - BioSpace
Xenetic presents preclinical data on DNase I with CAR-T therapy - Investing.com Nigeria
Xenetic (XBIO) Reveals Promising Preclinical Results for CAR-T Therapy - GuruFocus
Xenetic presents preclinical data on DNase I with CAR-T therapy By Investing.com - Investing.com South Africa
Xenetic Biosciences, Inc.: Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and Survival - FinanzNachrichten.de
After CAR-T failure, DNase I tied to tumor decline in pediatric lymphoma case - Stock Titan
Michael Liu and MJL Manager LLC report stakes in Xenetic Biosciences (NASDAQ: XBIO) - Stock Titan
XBIO Q2 2025 Earnings: Loss Narrows Despite No Revenue as Biotech Advances PipelineEPS Growth Report - newsline.com
Xenetic Biosciences (XBIO) Modestly Advances as Biotech Stock Tests Key Resistance ZoneVolume Climax - The Legal Advocate
Xenetic Biosciences Q2 2025 Earnings: Narrowed Loss Exceeds Expectations Amid Oncology Pipeline Progress - The Legal Advocate
Xenetic Biosciences (XBIO) Bounces 3.03%, Holding Above Key SupportBreakout Confirmation - newsline.com
Xenetic Biosciences Q2 2025 Earnings: Narrowed Loss Beats Estimates as Pipeline AdvancesPre-Earnings Drift - Newser
Xenetic Biosciences Shares Edge Down Ahead of ASCO Update - Bez Kabli
XBIO Stock Price, Quote & Chart | XENETIC BIOSCIENCES INC (NASDAQ:XBIO) - ChartMill
Xenetic Biosciences (XBIO) Q2 2025 Earnings Roar: $-0.45 EPS Tops Street ViewCommunity Momentum Stocks - Newser
Xenetic Biosciences (XBIO) Declines -3.75% Amid Market Weakness 2026-05-18Community Watchlist Picks - Newser
Contact Us – Inside INdiana BusinessXenetic Biosciences, Inc.Common Stock (Nasdaq:XBIO) Stock Quote - FinancialContent
TradingKey - TradingKey
Renaissance Holdings Reports 137,440 XBIO Shares (NASDAQ: XBIO) - Stock Titan
Xenetic (XBIO) Reports Strong Q1 Revenue Growth - GuruFocus
Xenetic Virtually Unchanged - Baystreet.ca
Xenetic Biosciences Reports Q1 2026 Results: Advances DNase Oncology Platform, Grows Royalty Revenue, and Strengthens Financial Position - Minichart
Xenetic Biosciences' Q1 royalty revenue rises, net loss narrows - TradingView
Xenetic Biosciences Q1 2026: Royalty Revenue Up 36%, Net Loss Narrows to $0.5M - TradingView
Xenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology Platform - ACCESS Newswire
Xenetic Biosciences (NASDAQ: XBIO) Q1 2026 results show higher royalties, lower loss - Stock Titan
Cancer study OK, smaller loss put Xenetic’s DNase therapy in focus - Stock Titan
Xenetic Biosciences: Q1 Earnings Snapshot - marketscreener.com
Xenetic Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Strategic review and smaller loss at Xenetic Biosciences (NASDAQ: XBIO) - Stock Titan
Xenetic’s Next Test: An ASCO Readout And The Cash Question - Finimize
Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting - Times Herald
Xenetic Biosciences Grants Equity Award to Interim CEO - The Globe and Mail
Xenetic Biosciences, Inc. Files Form 8-K Announcing Restricted Stock Award Agreement for CEO James Parslow - Minichart
Xenetic Biosciences, Inc. 2025 Annual Report 10-K/A: Executive Compensation, Governance, and Shareholder Information - Minichart
Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting - Times Argus
Xenetic Biosciences (NASDAQ: XBIO) updates CEO pay, ownership in 10-K/A - Stock Titan
Xenetic Biosciences (NASDAQ: XBIO) grants CEO/CFO 100,000 restricted shares - Stock Titan
Xenetic Biosciences (XBIO) interim CEO awarded 100,000-share restricted stock grant - Stock Titan
Xenetic Biosciences (XBIO) Stock: Market Sentiment Analysis | Q2 2025: EPS Tops ViewsAnalyst Consensus Shift - newsline.com
Cancer drug research from Xenetic gets June poster slot at ASCO - Stock Titan
Xenetic Biosciences (XBIO) Stock: Pricing Analysis (Momentum Fading) 2026-04-20Resistance Breakout - Xã Vĩnh Công
Xenetic Biosciences Inc (XBIOW) - Minichart
Xenetic Biosciences (XBIO) Stock Rallies on Launch (Bullish Sentiment) 2026-04-15Real-time Trade Ideas - Cổng thông tin điện tử tỉnh Lào Cai
1.79%
0.89%
자본화:
|
볼륨(24시간):